Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Odiparcil - Inventiva Pharma

Drug Profile

Odiparcil - Inventiva Pharma

Alternative Names: 424323; IVA336; SB 424323

Latest Information Update: 13 Nov 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Fournier Pharma
  • Developer Fournier Pharma; GlaxoSmithKline; Inventiva Pharma; Solvay
  • Class Antithrombotics; Glycosides; Small molecules
  • Mechanism of Action Glycosaminoglycan modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Mucopolysaccharidosis VI
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Mucopolysaccharidosis VI
  • Preclinical Mucopolysaccharidosis I; Mucopolysaccharidosis II
  • Discontinued Atrial fibrillation; Deep vein thrombosis; Stroke; Thrombosis

Most Recent Events

  • 22 Oct 2019 Inventiva Pharma completes phase II iMProveS trial in Mucopolysaccharidosis VI in the United Kingdom, France, Germany, Portugal (PO, Tablet) (NCT03370653)
  • 14 Jun 2019 Inventiva Pharma completes enrolment in the phase II iMProveS trial for Mucopolysaccharidosis VI in United Kingdom, France, Germany and Portugal
  • 05 Mar 2019 Odiparcil receives Rare Paediatric Disease Designation from the US FDA for Mucopolysaccharidosis VI
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top